Education
About Us
Working with TipRanks
Follow Us
3SBio, Inc. (HK:1530)
:1530
1530 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$5.47 - HK$13.74
Previous CloseN/A
Volume7.16M
Average Volume (3M)56.75M
Market Cap
HK$29.73B
Enterprise ValueHK$16.47B
Total Cash (Recent Filing)¥2.69B
Total Debt (Recent Filing)¥4.84B
Price to Earnings (P/E)13.3
Beta0.81
Next Earnings
Aug 20, 2025EPS Estimate
0.55Next Dividend Ex-Date
Jul 21, 2025Dividend Yield3.29%
Share Statistics
EPS (TTM)0.94
Shares Outstanding2,397,895,000
10 Day Avg. Volume64,355,285
30 Day Avg. Volume56,754,096
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)N/A
Price to Sales (P/S)2.80
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$11.40Price Target Upside-8.04% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
3SBio News
PremiumCompany Announcements
3SBio, Inc. Reports Strong Financial Growth in 2024
PremiumCompany Announcements
3SBio Announces Strong Financial Results for 2024
PremiumCompany Announcements
3SBio Announces Final Dividend for 2024
PremiumCompany Announcements
3SBio Partners with Duality Biologics for HER2 ADC Drug Commercialization
PremiumCompany Announcements
3SBio Cancels Treasury Shares and Relocates OfficePremiumCompany Announcements
3SBio Partners with Sunshine Lake Pharma for Drug Rights---
Bulls Say, Bears Say
Bulls Say
Market PositionTPIAO's sales increased 20.4% YoY to RMB5.1bn, becoming the leading drug in China's thrombocytopenia treatment market, with stable pricing and increasing penetration.
Pipeline Expansion3SBio has expanded its pipeline through strategic in-licensing, acquiring four key assets, including Paclitaxel Oral Solution which has received NMPA approval.
Revenue Growth3SBio delivered a strong performance with revenue increasing 16.5% YoY to RMB9.1bn, driven by the robust growth of TPIAO, Mandi and other products.
Bears Say
Dividend Payout3SBio has declared a final dividend of HK$0.25/shares, for a payout ratio of ~29%.
Sales Expectations2H24 sales were 3% ahead of Morgan Stanley estimates and 5% above VA consensus, thanks to the strength of TPIAO and Mandi.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
3.89%
Mutual Funds
― Other Institutional Investors
92.96% Public Companies and
Individual Investors
1530 FAQ
What was 3SBio, Inc.’s price range in the past 12 months?
3SBio, Inc. lowest stock price was HK$5.47 and its highest was HK$13.74 in the past 12 months.
What is 3SBio, Inc.’s market cap?
3SBio, Inc.’s market cap is HK$29.73B.
When is 3SBio, Inc.’s upcoming earnings report date?
3SBio, Inc.’s upcoming earnings report date is Aug 20, 2025 which is in 127 days.
How were 3SBio, Inc.’s earnings last quarter?
3SBio, Inc. released its earnings results on Mar 25, 2025. The company reported HK$0.439 earnings per share for the quarter, missing the consensus estimate of HK$0.455 by -HK$0.016.
Is 3SBio, Inc. overvalued?
According to Wall Street analysts 3SBio, Inc.’s price is currently Overvalued.
Does 3SBio, Inc. pay dividends?
3SBio, Inc. pays a Annually dividend of HK$0.25 which represents an annual dividend yield of 3.29%. See more information on 3SBio, Inc. dividends here
What is 3SBio, Inc.’s EPS estimate?
3SBio, Inc.’s EPS estimate is 0.55.
How many shares outstanding does 3SBio, Inc. have?
3SBio, Inc. has 2,397,895,000 shares outstanding.
What happened to 3SBio, Inc.’s price movement after its last earnings report?
3SBio, Inc. reported an EPS of HK$0.439 in its last earnings report, missing expectations of HK$0.455. Following the earnings report the stock price went down -7.613%.
Which hedge fund is a major shareholder of 3SBio, Inc.?
Currently, no hedge funds are holding shares in HK:1530
---
3SBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$11.40 (-8.04% Downside)
HK$11.40 (-8.04% Downside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.25%
12-Months-Change
Fundamentals
Return on Equity
14.19%
Trailing 12-Months
Asset Growth
-0.42%
Trailing 12-Months
Company Description
3SBio, Inc.
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
---
1530 Stock 12 Month Forecast
Average Price Target
HK$11.40
▼(-8.04% Downside)
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Best Analysts Covering 1530
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
+15.25%
reiterated a buy rating 19 days ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +15.25% per trade.
---